REG - Oxford Biomedica PLC - Oxford BioMedica plc Director's Share Purchase <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

29/10/2014 11:41

RNS Number : 1846U
Oxford Biomedica PLC
14 October 2014
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 13 October 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy company, was informed that, on 13 October 2014, one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:




Interest after purchase
Director / PDMR
Title
Price per share (p)
Number of Ordinary Shares acquired on
13 October 2014
Number of Ordinary Shares
% of total
issued share capital
Paul Blake
Chief Development Officer
4.1p
243,902
2,311,999
0.09%
The issued share capital of the Company is 2,565,392,419 1p ordinary shares.
-Ends-
For further information, please contact:

Oxford BioMedica plc: 
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Media Enquiries:
Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton
Consilium Strategic Communications
Tel: +44 (0)20 7309 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSDGBDGLBBBGSX